真性红细胞增多症诊断与治疗中国专家共识(2016年版)

2016-04-27 中华医学会血液学分会 中华血液学杂志, 2016,37(04): 265-268.

近十年来,真性红细胞增多症(polycythemia vera,PV)的诊治认识有了长足的进步。为给我国血液科医师提供规范化的临床实践指导,由中华医学会血液学分会白血病淋巴瘤学组牵头,广泛征求国内专家意见,结合我国现况,反复多次修改,从PV的诊断程序、实验室检查、诊断标准和治疗原则等方面最终达成本共识。该共识主要涉及诊断程序、诊断标准、预后判断标准、治疗、疗效判断标准几大方面内容。

中文标题:

真性红细胞增多症诊断与治疗中国专家共识(2016年版)

发布日期:

2016-04-27

简要介绍:

近十年来,真性红细胞增多症(polycythemia vera,PV)的诊治认识有了长足的进步。为给我国血液科医师提供规范化的临床实践指导,由中华医学会血液学分会白血病淋巴瘤学组牵头,广泛征求国内专家意见,结合我国现况,反复多次修改,从PV的诊断程序、实验室检查、诊断标准和治疗原则等方面最终达成本共识。
该共识主要涉及诊断程序、诊断标准、预后判断标准、治疗、疗效判断标准几大方面内容。


下载附件:

(因为版权问题,不支持下载)

评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1220403, encodeId=a2b71220403ce, content=<a href='/topic/show?id=8012e2649f1' target=_blank style='color:#2F92EE;'>#真性红细胞增多症#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72649, encryptionId=8012e2649f1, topicName=真性红细胞增多症)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Tue May 17 16:40:00 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973126, encodeId=c72c9e312699, content=好用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210612/16da5f2fb9814256ad265b1a785c6903/8e1179b96a0f41458bc5fbf4eb1d8da4.jpg, createdBy=333d5519843, createdName=ms2000000173324166, createdTime=Sat Jun 12 18:36:10 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363222, encodeId=85f43632222b, content=很受用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9ac02321722, createdName=1224f578m26(暂无昵称), createdTime=Tue Mar 19 22:57:22 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333697, encodeId=1de833369e05, content=谢谢分享给我, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=981b2401455, createdName=12355bb4m53(暂无昵称), createdTime=Mon Jul 23 23:01:16 CST 2018, time=2018-07-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1220403, encodeId=a2b71220403ce, content=<a href='/topic/show?id=8012e2649f1' target=_blank style='color:#2F92EE;'>#真性红细胞增多症#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72649, encryptionId=8012e2649f1, topicName=真性红细胞增多症)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Tue May 17 16:40:00 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973126, encodeId=c72c9e312699, content=好用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210612/16da5f2fb9814256ad265b1a785c6903/8e1179b96a0f41458bc5fbf4eb1d8da4.jpg, createdBy=333d5519843, createdName=ms2000000173324166, createdTime=Sat Jun 12 18:36:10 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363222, encodeId=85f43632222b, content=很受用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9ac02321722, createdName=1224f578m26(暂无昵称), createdTime=Tue Mar 19 22:57:22 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333697, encodeId=1de833369e05, content=谢谢分享给我, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=981b2401455, createdName=12355bb4m53(暂无昵称), createdTime=Mon Jul 23 23:01:16 CST 2018, time=2018-07-23, status=1, ipAttribution=)]
    2021-06-12 ms2000000173324166

    好用

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1220403, encodeId=a2b71220403ce, content=<a href='/topic/show?id=8012e2649f1' target=_blank style='color:#2F92EE;'>#真性红细胞增多症#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72649, encryptionId=8012e2649f1, topicName=真性红细胞增多症)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Tue May 17 16:40:00 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973126, encodeId=c72c9e312699, content=好用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210612/16da5f2fb9814256ad265b1a785c6903/8e1179b96a0f41458bc5fbf4eb1d8da4.jpg, createdBy=333d5519843, createdName=ms2000000173324166, createdTime=Sat Jun 12 18:36:10 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363222, encodeId=85f43632222b, content=很受用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9ac02321722, createdName=1224f578m26(暂无昵称), createdTime=Tue Mar 19 22:57:22 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333697, encodeId=1de833369e05, content=谢谢分享给我, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=981b2401455, createdName=12355bb4m53(暂无昵称), createdTime=Mon Jul 23 23:01:16 CST 2018, time=2018-07-23, status=1, ipAttribution=)]
    2019-03-19 1224f578m26(暂无昵称)

    很受用

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1220403, encodeId=a2b71220403ce, content=<a href='/topic/show?id=8012e2649f1' target=_blank style='color:#2F92EE;'>#真性红细胞增多症#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72649, encryptionId=8012e2649f1, topicName=真性红细胞增多症)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Tue May 17 16:40:00 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973126, encodeId=c72c9e312699, content=好用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210612/16da5f2fb9814256ad265b1a785c6903/8e1179b96a0f41458bc5fbf4eb1d8da4.jpg, createdBy=333d5519843, createdName=ms2000000173324166, createdTime=Sat Jun 12 18:36:10 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363222, encodeId=85f43632222b, content=很受用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9ac02321722, createdName=1224f578m26(暂无昵称), createdTime=Tue Mar 19 22:57:22 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333697, encodeId=1de833369e05, content=谢谢分享给我, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=981b2401455, createdName=12355bb4m53(暂无昵称), createdTime=Mon Jul 23 23:01:16 CST 2018, time=2018-07-23, status=1, ipAttribution=)]
    2018-07-23 12355bb4m53(暂无昵称)

    谢谢分享给我

    0